Carbylan was founded in 2005 to develop and market medical devices and device/drug combination products based on chemically engineered polymers of hyaluronic acid, a well known polysaccharide widely present in the human body.
Its initial market focus is therapeutic medical devices for rhinosinusitis and osteoarthritis. Carbylanâ€™s proprietary technology enables delivery of biomaterial-based medical devices as injectable liquids that self-polymerize inside the body to form therapeutic implants that covalently bind to tissues at the target delivery site.
Past Team (2)Update
Funding Rounds (2) - $26MUpdate
3181 Porter Drive
Palo Alto, CA 94304